Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCR | P30988 | 4/20 | 0.72 |
| ▸ | GLP1R | P43220 | 3/20 | 0.66 |
| ▸ | GCGR | P47871 | 3/20 | 0.66 |
| ▸ | TFPI | P10646 | 3/20 | 0.66 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.66 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.66 |
| ▸ | NPY2R | P49146 | 7/20 | 0.64 |
| ▸ | NPY4R | P50391 | 7/20 | 0.64 |
| ▸ | NPY5R | Q15761 | 7/20 | 0.64 |
| ▸ | NPY1R | P25929 | 5/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29872608 | 0.98 | CALCR (0.75) | CALCRGLP1RGCGRTFPICRHR1 | |
| SCHEMBL30423615 | 0.89 | CALCR (0.74) | CALCRGLP1RGCGRCRHR1CRHR2 | |
| SCHEMBL30658211 | 0.89 | CALCR (0.71) | CALCRGLP1RGCGRTFPICRHR1 | |
| Human Neuropeptide Y SCHEMBL29523348 | 0.89 | CALCR (0.72) | CALCRGLP1RGCGRCRHR1CRHR2 | |
| SCHEMBL29767063 | 0.89 | CALCR (0.79) | CALCRGLP1RGCGRCRHR1CRHR2 | |
| SCHEMBL29570760 | 0.89 | NPY2R (0.69) | CALCRTFPINPY2RNPY4RNPY5R | |
| SCHEMBL30436462 | 0.89 | CALCR (0.70) | CALCRGLP1RGCGRCRHR1CRHR2 | |
| SCHEMBL29975560 | 0.89 | NPY2R (0.69) | CALCRTFPINPY2RNPY4RNPY5R | |
| SCHEMBL31182609 | 0.89 | CALCR (0.71) | CALCRGLP1RGCGRTFPICRHR1 | |
| SCHEMBL29377468 | 0.88 | CALCR (0.73) | CALCRGLP1RGCGRTFPICRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11428694-B2 | Detection methods employing HCV core lipid and DNA binding domain monoclonal antibodies | ABBOTT LABORATORIES (US) | 2022-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11428694-B2 | Detection methods employing HCV core lipid and DNA binding domain monoclonal antibodies | CD2BP2, HAVCR2, FABP1 | CALCR 3413/4885GLP1R 2906/4885GCGR 2492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.